Gyl Financial Synergies, LLC Gilead Sciences, Inc. Transaction History

Gyl Financial Synergies, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$71.58 - $87.29 $5,368 - $6,546	75 Added 0.82%	9,234 $676,000
Q4 2023 Feb 09, 2024	SELL	$73.27 - $83.09 $61,839 - $70,127	-844 Reduced 8.44%	9,159 $741,000
Q3 2023 Nov 06, 2023	SELL	$73.94 - $80.67 $20,407 - $22,264	-276 Reduced 2.69%	10,003 $749,000
Q2 2023 Aug 14, 2023	BUY	$76.01 - $86.7 $4,788 - $5,462	63 Added 0.62%	10,279 $792,000
Q1 2023 May 15, 2023	SELL	$77.31 - $88.08 $154,001 - $175,455	-1,992 Reduced 16.32%	10,216 $847,000
Q4 2022 Feb 06, 2023	BUY	$62.32 - $89.47 $99,525 - $142,883	1,597 Added 15.05%	12,208 $1.05 Million
Q3 2022 Nov 01, 2022	SELL	$59.54 - $68.01 $2,083 - $2,380	-35 Reduced 0.33%	10,611 $655,000
Q2 2022 Aug 01, 2022	BUY	$57.72 - $65.01 $103,491 - $116,562	1,793 Added 20.25%	10,646 $658,000
Q1 2022 May 05, 2022	BUY	$57.92 - $72.58 $299,678 - $375,528	5,174 Added 140.64%	8,853 $526,000
Q1 2019 May 14, 2019	BUY	$62.53 - $70.05 $230,047 - $257,713	3,679 New	3,679 $239,000

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Gyl Financial Synergies, LLC, based on Form 13F filings with the SEC.

Stay updated on Gyl Financial Synergies, LLC with notifications on news.